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Simian varicella virus (SVV) infection in primates closely resembles varicella-zoster virus (VZV) infection in humans. SVV ORF 63 has 51.6%
homology at the amino acid level to VZVORF 63. We cloned SVVORFs 63 and 62, transcribed and translated in vitro, and immunoprecipitated the
expected proteins with rabbit polyclonal antibodies. Immunoprecipitation analysis revealed that SVV ORF 63 is expressed as a 43-kDa
phosphorylated protein in virus-infected cells. In both neuronal and non-neuronal cells, SVV ORF 62 protein alone upregulated the SVV 21
promoter, while SVV ORF 63 protein alone did not have any effect. SVV ORF 62-mediated transactivation of the SVV ORF 21 promoter was
upregulated in neuronal cells, but downregulated in non-neuronal cells, by SVV ORF 63 protein. This is the first study in which a varicella protein
(ORF 63) expressed during latency has been shown to have a differential effect on a promoter that is also active during latency, in neuronal as
compared to non-neuronal cells.
D 2005 Elsevier Inc. All rights reserved.Keywords: Simian varicella virus; ORF 63; Neuronal cells; Non-neuronal cellsIntroduction
Simian varicella virus (SVV) infection of primates shares
many clinical and immunovirological features with human
varicella zoster virus (VZV). At the molecular level, analysis
of the complete nucleotide sequence of 124,139 base pairs of the
SVV genome (Gray et al., 2001) has revealed 69 potential open
reading frames (ORFs), several of which are highly homologous
to VZV ORFs. During latency in human ganglia, no less than
five VZV genes (ORFs 21, 29, 62, 63, and 66) are transcribed.
SVVand VZV ORFs 62 and 63 share 58% and 52% amino acid
identity, respectively (Gray et al., 1995). While the regulatory
function of VZV ORF 63 is controversial (Jackers et al., 1992;
Kost et al., 1995, Bontems et al., 2002), VZV ORF 62 has been0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.045
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subbiah.pugazhenthi@uchsc.edu (S. Pugazhenthi).shown to transactivate all putative kinetic classes of VZV genes
(Baudoux et al., 1995; Inchauspe and Ostrove, 1989; Inchauspe
et al., 1989; Perera et al., 1992). It is not known whether SVV
ORF 62 and 63 regulate other SVV genes.
We have identified the SVVORF 21 promoter and shown that
SVV infection is essential for its activity (Mahalingam et al.,
2000). Herein, we questioned whether SVV ORF 62 and 63
activate theSVVORF21promoter and ifSVVORF63 influences
transactivationbySVVORF62.BecauseSVV, likeVZV, is latent
in ganglionic neurons (Kennedy et al., 2004), we also studied the
effect of SVV 63 protein on SVV ORF 62 transactivation of the
SVV 21 promoter in both neuronal and non-neuronal cells.
Results
SVV and VZV ORF 63 share amino acid homology
SVV and VZV ORF 63 are predicted to encode 29.3- and
30.5-kDa polypeptides, respectively (Davison and Scott, 1986;6) 244 – 250
www.e
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amino acid homology (Gray et al., 1995). Comparison of the
two amino acid sequences (Fig. 1) revealed several interesting
features: amino acids 26–157 in VZV ORF 63, referred to as
region 2, shares 67% amino acid identity with the region 2
segment of SVV ORF 63. Region 2 is highly conserved
between different alpha herpesviruses and is predicted to
mediate binding to homologs of VZV ORF 62 (Baiker et al.,
2004). Specifically, amino acid residues R59 and L60 of VZV
ORF 63 are important for VZV ORF 62 binding (Baiker et al.,
2004). These two amino acids are the same in the VZV and
SVV 63 ORFs. Residues S165, S173, and S185 are sites of
phosphorylation by cellular kinases (Bontems et al., 2002;
Stevenson et al., 1996), and two of these serine residues (S165
and S173) are conserved in SVV ORF 63. The nuclear
localization signals are in the carboxyl terminus (amino acids
142–210) of VZV ORF 63 (Stevenson et al., 1996), a region of
SVV ORF 63 that shares 48% amino acid identity with its VZV
counterpart. Of two nuclear localization signals (KRRR; 260–
263 and KRPQ; 226–229) (Baiker et al., 2004; Stevenson et
al., 1996), one (KRPR, 225–228) is shared by SVV ORF 63.
Cloning of SVV ORFs 62 and 63 into an expression vector
Based on the published sequence of the inverted repeat
regions of the SVV genome (Gray et al., 2001), SVV ORFs 62
and 63 were cloned into the expression vector pCI-neo,
downstream from the CMV promoter (Fig. 2).
Expression in vitro and immunoprecipitation of SVV ORFs
62 and 63
Size and specificity of the polypeptide encoded by the
recombinant clones containing SVV ORFs 62 or 63 were
determined using in vitro translation (ivt) of RNAs transcribedFig. 1. Predicted amino acid sequences of SVV ORF 63 and VZV ORF 63 and their a
amino acids. Numbers on the left indicate the amino acid positions, where 1 is the
phosphorylated by cellular kinases (#) are indicated below the sequence. Lines indicafrom linearized recombinant plasmids in the rabbit reticulo-
cyte system. SDS-PAGE revealed a major band at the 165-
kDa position for SVV ORF 62. The protein was absent when
no RNA was used for translation. The 165-kDa protein was
immunoprecipitated with rabbit anti-SVV antiserum, but not
with preimmune serum or when no RNA was used in the ivt
reaction (Fig. 3A). Thus, the recombinant clone encoding
SVV 62 ORF probably contains the complete polypeptide.
The translated SVV ORF 62 was much larger than the size
predicted (136.8 kDa) based on the nucleotide sequence
(Gray et al., 2001), consistent with previous observations
(Forghani et al., 1990).
SDS-PAGE analysis of the polypeptide encoded by SVV
ORF 63 and transcribed and translated using the rabbit
reticulocyte system from a linearized recombinant plasmid
containing SVV ORF 63 DNA revealed a major band at 41
kDa (Fig. 3B). The protein was absent when RNA was
omitted from the translation reaction. The 41-kDa product
did not react with rabbit anti-SVV antiserum (data not
shown). Based on the amino acid homology of the SVV and
VZV ORF 63, we used rabbit anti-VZV 63 serum, which
has been used to identify VZV gene 63 protein in human
ganglia (Mahalingam et al., 1996), for immunoprecipitation.
A 41-kDa translation product was immunoprecipitated, while
use of a rabbit preimmune serum or absence of RNA in the
translation reaction revealed no such band (Fig. 3B). The
observed size of the SVV ORF 63 was much larger than
the size predicted (29.3 kDa) by the nucleotide sequence
(Gray et al., 2001), as previously observed using VZV ORF
63 (Davison and Scott, 1986; Kinchington et al., 1995).
Two other polypeptides (30–35 kDa) were also immuno-
precipitated with rabbit-anti-VZV 63 antiserum. These could
be degradation products since protein of similar sizes
was also seen in the immunoprecipitation of ivt products in
Fig. 3B.lignment. Consensus sequences are indicated. Shaded regions indicate identical
initiation codon for both viruses. ORF 62 binding sites (*) and serine residues
te predicted nuclear localization signals on VZVand SVV ORF 63, respectively.
Fig. 2. Cloning of SVV ORFs 62 and 63. A recombinant plasmid containing the SVV BamHI-D fragment (11.15 kbp), containing the unique long (UL), long
inverted repeat (IRL), and short inverted repeat (IRS) sequences, was cleaved with SnaBI and AspI. The 4544-bp AspI –SnaBI fragment encoding SVV ORF 62 and
the 1350-bp SnaBI–BamHI fragment encoding SVV ORF 63 were cloned into the expression vector pCI-neo downstream from the CMV promoter.
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Immunoprecipitation of [35S]methionine-labeled uninfected
(BSC-1) or SVV-infected (BSC-1–SVV) cell lysates with
rabbit preimmune serum or rabbit anti-VZV 63 antiserum
followed by SDS-PAGE analysis revealed a 41-kDa 35S-
labeled band in SVV-infected cells, but not in uninfected cells
(Fig. 4). These results, together with the immunoprecipitation
data in Fig. 3B, indicate that SVV ORF 63 encodes a 41-kDa
protein.Fig. 3. In vitro expression and immunoprecipitation of SVV ORFs 62 (A) and 63 (
linearized with NotI and used as templates for in vitro transcription. The RNAs were
products were immunoprecipitated with rabbit preimmune serum, rabbit anti-SVV a
product and immunoprecipitates were analyzed by SDS-PAGE. Molecular mass mar
ORFs 62 (165 kDa) and 63 (41 kDa) are indicated. Results from control experimeSimilar analyses of SVV-infected cell lysates labeled
with [32P]pyrophosphate detected a 43-kDa phosphorylated
protein in virus-infected cells (Fig. 4), but not in unin-
fected cells (data not shown) immunoprecipitated with
rabbit anti-VZV 63 antiserum. The difference in the size
between the 35S-labeled (41 kDa) and 32P-labeled (43 kDa)
SVV ORF 63 protein could reflect alterations in migration
because of phosphorylation and the presence of multiple
phosphorylation sites as previously described for VZV gene
63 protein (Debrus et al., 1995). Thus, in Fig. 4,B) proteins. Recombinant plasmids containing either SVV ORF 62 or 63 were
translated in vitro (ivt) in the presence of [35S]methionine, and the radiolabeled
ntiserum, or rabbit polyclonal antibodies raised against VZV ORF 63. The ivt
kers and the apparent molecular size of the major polypeptides encoded by SVV
nts in which RNA was omitted in the ivt reaction are shown.
Fig. 5. Transactivation of the SVV ORF 21 promoter by SVV ORFs 62 and 63
in neuronal and non-neuronal cells in culture. Monolayers of monkey kidney
(Vero) (A), human melanoma (MeWo) (B), or human neuroblastoma (SH-SY-
5Y) (C) cells cultured in 12-well plates to 70% confluence were transfected
with 800 ng of a plasmid containing firefly-luciferase driven by the SVV ORF
21 promoter, along with varying amounts of recombinant clones containing
SVV ORF 62 or 63. The quantity (ng) of the SVV ORF 62-containing plasmid
is shown on the x axis. For each time point, the total amount of DNA was
brought to 2000 ng by addition of either vector DNA or SVV ORF 63-
containing plasmid. Cells were lysed 24 h after transfection and assayed for
luciferase using the dual luciferase assay kit (Promega). Firefly-luciferase
activities were normalized with Renilla luciferase activity, an internal control
for transfection efficiency. Results are given as fold activation over the activity
observed when SVV ORF 21 promoter was used without SVV gene 62 DNA.
Values represent the mean (TSE) for 3 independent experiments. P < 0.001
when activation by SVV ORF 62 alone was compared to vector control. P <
0.01 when SVV ORF 62 and 63 was compared to SVV ORF 62 alone. SVV
ORF 21 promoter is activated by SVV ORF 62 but not by SVV ORF 63.
Downregulation of SVV ORF 62 transactivation of SVV ORF 21 promoter by
SVV ORF 63 is observed in non-neuronal but not in neuronal cells.
Fig. 4. Expression and immunoprecipitation of SVV ORF 63 product in virus-
infected cells. Uninfected (BSC-1) or SVV-infected (BSC-1–SVV) cells
labeled with either [35S]methionine or [32P]pyrophosphate were lysed and
immunoprecipitated with rabbit preimmune serum or rabbit polyclonal
antibodies directed against VZV 63. Immunoprecipitates were analyzed by
SDS-PAGE. Molecular mass markers and the apparent molecular size of the
labeled polypeptides encoded by SVV ORF 63 are shown.
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labeled 41 kDa.
SVV ORF 63 protein upregulates transactivation of the SVV
ORF 21 promoter by SVV ORF 62 in neuronal, but not in
non-neuronal cells
SVV ORF 62 transactivation of the SVV ORF 21 promoter
and the effect of SVV ORF 63 on this transactivation were
assessed in non-neuronal (Vero and MeWo) and neuronal (SK-
SY-5Y) cells co-transfected with a mixture of recombinant
plasmids (2000 ng) containing varying amounts of SVV ORFs
62 and 63 along with a plasmid containing the SVV ORF 21
promoter that drives the luciferase reporter gene. All transfec-
tion results were normalized to Renilla luciferase which was
used as an internal control. Therefore, the observations were
independent of the differences in transfection efficiencies
between cell lines. In both non-neuronal cell lines, SVV
ORF 62 activated the SVV ORF 21 promoter and SVV ORF
63 by itself did not activate the SVV 21 promoter but did
suppress the ability of SVV ORF 62 to transactivate the SVV
ORF 21 promoter (Figs. 5A and B); suppression was ¨30% in
Vero cells and ¨50% in MeWo cells. The influence of SVV
ORF 63 on SVV ORF 62 activation in non-neuronal cells was
evident with as little as 50 ng of plasmid containing SVV ORF
62 used in transfection. In contrast, SVV ORF 63 did not
suppress activation of the SVV ORF 21 promoter by SVV
ORF 62 in neuronal cells (Fig. 5C).
Similar analyses were carried out using a constant amount
(50 ng) of SVV ORF 62 plasmid DNA and varying amounts
(0–1200 ng) of SVV ORF 63 in transfection of two differenthuman neuronal cell lines (SH-SY-5Y and SKNMC) and non-
neuronal cells. In non-neuronal cells transfected with 50 ng of
SVV ORF 62 without SVV ORF 63, SVV ORF 21 promoter
activity was increased 50-fold; with increasing concentrations
of SVV ORF 63 (300–1200 ng), activation decreased to 30-
fold (Fig. 6A). In both neuronal cell lines, only 5-fold
activation was observed when 50 ng of SVV ORF 62 was
used alone in transfection without SVV ORF 63; with
increasing concentrations of SVV ORF 63 (300–1200 ng),
activation rose to 20-fold in SH-SY-5Y cells and to 10-fold in
Fig. 6. Effect of varying concentrations of SVV ORF 63-containing plasmid on
transactivation by a constant amount of SVV ORF 62-containing plasmid.
Monolayers of human melanoma (MeWo) (A) or human neuroblastoma cells
(SH-SY-5Y or SKNMC) (B and C) cultured in 12-well plates to 70%
confluence were transfected with 700 ng of a plasmid containing firefly-
luciferase driven by the SVV ORF 21 promoter, or 50 ng of the plasmid
containing SVV ORF 62, and varying amounts of recombinant clones
containing SVV ORF 63. The quantity (ng) of SVV ORF 63-containing
plasmid is shown on the x axis. For each time point, the total quantity of DNA
was brought to 1950 ng by addition of either vector DNA pCI-neo. Cells were
lysed 24 h after transfection and assayed for luciferase using the dual luciferase
assay kit (Promega). Firefly-luciferase activities were normalized with Renilla
luciferase activity, an internal control for transfection efficiency. Results are
given as fold activation over the observed activity when SVV ORF 21 promoter
was used without SVV gene 62 DNA. Values represent the mean (TSE) for 3
independent experiments. **P < 0.001 when compared to vector control. *P <
0.01 when compared to promoter + SVV ORF 62. Overall, the activity of SVV
ORF 62 is downregulated by SVV ORF 63 in non-neuronal cells and
upregulated in neurons.
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obtained when the quantity of SVV ORF 62 was maintained at
200 ng with varying quantities of SVV ORF 63 (data not
shown). Overall, increasing concentrations of SVV ORF 63
was accompanied by downregulated SVV ORF 62 activity in
non-neuronal cells but upregulated activity in neuronal cells.Discussion
ORF 63 appears to be the most prevalent transcript produced
from the five known VZV ORFs that are expressed during
latency in human ganglia (Cohrs et al., 2000). Nevertheless, the
exact role of varicella ORF 63 in latency and pathogenesis
remains unknown. Both VZV and SVV become latent in
ganglionic neurons. To determine whether varicella ORF 63
functions differently in neuronal cells compared to non-neuronal
cells, we cloned SVVORFs 62 and 63 into an expression vector,
identified their cognate proteins in vitro (Figs. 3 and 4), and
examined the influence of SVV ORF 63 protein on transactiva-
tion of the SVV 21 promoter by SVV ORF 62 in neuronal and
non-neuronal cells. SVV ORF 62 protein by itself transactivated
the SVV ORF 21 promoter 50- to 200-fold in non-neuronal cells
compared to 10- to 70-fold in neuronal cells (Figs. 5 and 6).
These findings are consistent with an earlier study in which VZV
ORF 62 transactivated the VZV ORF 28 promoter more in non-
neuronal (Vero) cells than in cells (ND7) of neuronal origin
(Bontems et al., 2002). Comparison of the effect of the SVV
ORF 63 protein on the transactivation function of SVV ORF 62
protein in non-neuronal and neuronal cells revealed a suppres-
sive activity of SVV ORF 63 protein on SVV ORF 62 induction
of the SVV ORF 21 promoter in non-neuronal cells. This
downregulation was more extensive in melanoma cells than in
Vero cells (Figs. 5A and B). Interestingly, VZV ORF 63 was
shown to upregulate transactivation of the VZV gI promoter by
VZV ORF 62 in non-neuronal T cells (Lynch et al., 2002).
In neuronal cells, SVV ORF 63 protein did not suppress
SVV ORF 62 protein activation of the SVV ORF 21 promoter;
in fact, the transactivation was slightly upregulated. Neverthe-
less, previous analysis of the effect of VZV gene 63 and VZV
gene 62 proteins on a different promoter (VZV ORF 28)
indicated downregulation in both non-neuronal and neuronal
cells (Bontems et al., 2002). Recently, it has been shown
(Zuranski et al., 2005) that, in transfection experiments, the
levels of varicella ORF 63 protein are equivalent in MeWo
(non-neuronal) and SK-SY-5Y (neuronal) cells, although its
influence on the transactivation of cellular promoters was cell-
type-specific.
Thus, the influence of varicella ORF 63 protein on ORF 62
function may be both cell-type-specific, as well as promoter-
specific. Furthermore, there could be some differences between
cells of neuronal origin and mature differentiated neurons in
monkeys.
Overall, SVV ORF 63 protein appears to function differ-
ently in neuronal than in non-neuronal cells. Further analysis of
varicella gene 63–protein interaction with other viral and
cellular genes may help to elucidate the mechanisms of
varicella pathogenesis and latency.
Materials and methods
Cells and viruses
African green monkey kidney cells (Vero cells) were used to
propagate SVV. Vero cell, human melanoma (MeWo) cells, and
R. Mahalingam et al. / Virology 345 (2006) 244–250 249two lines of human neuroblastoma cells (SH-SY-5Y and
SKNMC; American Type Culture Collection, Manassas, VA)
were used for transfections. Veros as well as MeWos are
permissive for SVV infection. SVV infection of SH-SY-5Y and
SKNMC cells has not been tested.
Alignment of SVV and VZV ORF 63 sequences
Based on the published sequences of the SVV (Gray et al.,
2001) and VZV (Davison and Scott, 1986) genomes, the
predicted amino acid sequences for ORF 63 were aligned using
Vector NTI Suite software (Invitrogen, Carlsbad, CA).
Cloning of SVV ORFs 62 and 63 into pCI-neo
A recombinant clone containing the SVV BamHI-D
fragment in pGem7Z (Promega, Madison, WI) was digested
with SnaBI and AspI, and the 4544-bp AspI–SnaBI and the
1350-bp SnaBI–BamHI fragments were isolated from agarose
gels, treated with T7 DNA polymerase, and ligated to SmaI-
digested and dephosphorylated pCI-neo (Clontech, Palo Alto,
CA). The ligation products were used to transform Top10F V-
competent cells (Invitrogen). Recombinant clones containing
the desired inserts were identified by restriction analysis.
In vitro transcription and translation
Recombinant clones containing SVV ORF 62 or 63 were
linearized by digestion with NotI and cleaned by phenol
extraction and ethanol precipitation. Linearized DNA (1 Ag)
was used in an in vitro transcription reaction with T7 RNA
Polymerase (Life Technologies, Gaithersburg, MD) according
to the manufacturer’s instructions. In-vitro-transcribed RNA
(3 Ag) was translated in the presence of [35S]methionine using
the nuclease-treated rabbit reticulocyte lysate system (Pro-
mega) as per the manufacturer’s instructions. The products
were analyzed using SDS-PAGE followed by autoradiography.
Transfections and luciferase assays
Plasmid DNAs were prepared using the endotoxin-free
Maxi-prep kit (Qiagen, Valencia, CA) and transfected using
LipofectAMINE 2000 reagent (Life Technologies) into Vero,
MeWo, or SKNMC, or SH-SY-5Y cells cultured in 12-well
plates to 70% confluence (Jambal et al., 2003). In the first
experiment, Vero, MeWo, or human neuroblastoma cells were
transfected with 800 ng of a plasmid containing firefly-
luciferase gene driven by the SVV ORF 21 promoter, together
with varying amounts of recombinant clones containing SVV
ORF 62 or 63 DNA. For each time point, the total quantity of
DNA was brought to 1200 ng by addition of vector DNA or
SVV ORF 63-containing plasmid. An internal control con-
sisted of 50 ng of a plasmid containing Renilla luciferase. The
total amount of DNA (including vector DNA, recombinant
DNAs containing SVV ORFs 62, 63, and SVV ORF 21
promoter, and plasmid containing Renilla luciferase) in each
transfection was 2050 ng. In the second experiment, cells weretransfected with a mixture of recombinant clones containing
SVV ORF 62 (50 ng) and varying amounts of SVV ORF 63
(0–1250 ng) and the plasmid containing the firefly-luciferase
gene driven by the SVV ORF 21 promoter (700 ng). All
transfections included 50 ng of recombinant plasmid contain-
ing Renilla luciferase to normalize for transfection efficiency.
The total amount of DNA in each transfection was 1950 ng. In
both experiments, cells at 24 h after transfection were washed
in PBS, scraped, and lysed and assayed for luciferase using the
dual luciferase assay kit (Promega). All results were relative to
the activity found when vector DNA was substituted for the
SVV ORF 62 plasmid. Statistical analysis was performed on
the transfection results using one-way analysis of variance with
Dunnett’s multiple comparison test.
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